Background
Prospective multicenter phase II, single-arm study. 53 patients with newly diagnosed MYC-rearranged high-grade B-cell lymphoma, including double-hit (MYC + BCL2 and/or BCL6) and triple-hit (DHL/THL) disease. Historically R-CHOP yielded dismal outcomes (median OS ~1 year). DA-EPOCH-R was tested as an alternative to very intensive regimens (R-HyperCVAD, CODOX-M/IVAC).
Interventions and follow up
Regimen: DA-EPOCH-R every 21d × 6 cycles (dose-adjusted etoposide/vincristine/doxorubicin CIV + cyclophosphamide + prednisone + rituximab) in newly diagnosed double-/triple-hit high-grade B-cell lymphoma (MYC + BCL2/BCL6 rearrangement)
Primary endpoint: Progression-free survival
Median follow-up: 48 months
Primary endpoint: Progression-free survival
Median follow-up: 48 months
Results
4-year PFS: 71% (DHL/THL combined)
4-year OS: 77%
CR rate: 72%
DHL-specific (MYC+BCL2): 4-year PFS 63%, 4-year OS 70%
THL (MYC+BCL2+BCL6): 4-year PFS 81%, 4-year OS 86%
4-year OS: 77%
CR rate: 72%
DHL-specific (MYC+BCL2): 4-year PFS 63%, 4-year OS 70%
THL (MYC+BCL2+BCL6): 4-year PFS 81%, 4-year OS 86%
Adverse events
Hematologic: Grade 4 neutropenia 100% (expected); febrile neutropenia 64%; grade 3/4 anemia 43%; grade 3/4 thrombocytopenia 53%.
Other: Treatment-related deaths 3 (sepsis); dose reductions required in the majority of patients at some point.
Other: Treatment-related deaths 3 (sepsis); dose reductions required in the majority of patients at some point.
Conclusions
DA-EPOCH-R achieved durable long-term remissions in DHL/THL — markedly better than historical R-CHOP outcomes — without the toxicity of very intensive induction regimens. These results challenged the perceived need for R-HyperCVAD or CODOX-M/IVAC in DHL.
Key Limitations
Single-arm, non-randomized phase II with small sample (n=53) and no concurrent comparator; outcomes benchmarked against historical R-CHOP data. Substantial hematologic toxicity (100% grade 4 neutropenia, 64% febrile neutropenia, 3 sepsis deaths). Generalizability to older or frail patients is limited, and no randomized trial has confirmed superiority over R-CHOP in DHL.
Clinical Context
DA-EPOCH-R is not an FDA-approved branded regimen but is a widely used standard for frontline MYC-rearranged high-grade B-cell lymphoma (double-/triple-hit). ASCO and ESMO guidance support intensified anthracycline-based regimens such as DA-EPOCH-R over R-CHOP for these aggressive tumors. No randomized trial has confirmed a survival advantage, and CNS prophylaxis is recommended given high CNS relapse risk.